Members-only Site   |   Print Page   |   Contact Us   |   Sign In   |   Register
News & Press: Breaking News

IACP Submits Comments on 503(a): Additions & Modifications to Removed List of Drug Products

Tuesday, September 2, 2014   (0 Comments)
Posted by: Dagmar Anderson
Share |




Today we have two important deadlines for regulatory comment with the FDA:  one for the proposed "do not compound" list and the second for the cGMP requirements associated with 503B outsourcing facilities.

IACP has just filed the first of the two IACP formal comments regarding the "do not compound" list focusing primarily on the agency's circumvention of the Pharmacy Compounding Advisory Committee and a lack of procedures for adding or modifying the list in the future. 


Please click here to read IACP's comments in their entirety.

Association Management Software Powered by YourMembership  ::  Legal